Advanced Accelerator Applications recently broke ground in Indianapolis on their planned $72 million, 60,000-square-foot new Radioligand Therapy manufacturing plant to be located on Challenger Drive.

The ceremony, which featured Gov. Eric Holcomb, company executives and local officials, was a masks-required festivity held Oct. 19, according to a press release from the Indiana Economic Development Corporation.

A subsidiary of Switzerland-based Novartis, Advanced Accelerator Applications is a pharmaceutical group specialized in the field of nuclear medicine, according to the release. The new Radioligand Therapy manufacturing plant in Indianapolis represents a significant expansion of the company’s U.S.-based manufacturing.

The new facility is expected to include “state-of-the-art, advanced manufacturing technologies, reflecting the latest innovations and radiopharmaceutical production,” according to the release. The company will begin with a limited production line, but plans to expand operations at the plant in the future.

Through 2022, the plant is expected to generate a total of 26 “high-wage” jobs, according to the release.